Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
More News related to OPTR
- After-Hours Movers 2/4: PWER, OPTR, PTIX, HA, TSYS Higher; PWAV, TTMI, MFLX, SNCR, BMI Lower
- Optimer Pharmaceuticals (OPTR) Announces Positive Phase 3 Results
- Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infection
- Ladenburg Thalmann Upgrades Optimer Pharmaceuticals (OPTR) to Buy
- Notable Insider Trades 12/29 (LM, OPTR, MED, CTXS, AM, COST, more...)
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Oppenheimer upgrades Optimer Pharmaceuticals (Nasdaq: OPTR) from Perform to Outperform. Price target $16.
To see more analyst ratings on OPTR Click Here.
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide.
Related Categories
UpgradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
